SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:gup.ub.gu.se/50284"
 

Sökning: id:"swepub:oai:gup.ub.gu.se/50284" > Economic implicatio...

Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial

Caro, J. J. (författare)
Migliaccio-Walle, K. (författare)
O'Brien, J. A. (författare)
visa fler...
Nova, W. (författare)
Kim, J. (författare)
Hauch, O. (författare)
Hillson, E. (författare)
Wedel, H. (författare)
Hjalmarson, Åke, 1937 (författare)
Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
Gottlieb, S. (författare)
Deedwania, P. C. (författare)
Wikstrand, John, 1938 (författare)
Gothenburg University,Göteborgs universitet,Hjärt-kärlinstitutionen,Wallenberglaboratoriet,Cardiovascular Institute,Wallenberg Laboratory
visa färre...
 (creator_code:org_t)
2005
2005
Engelska.
Ingår i: J Card Fail. - 1071-9164. ; 11:9, s. 647-56
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • BACKGROUND: The MERIT-HF trial demonstrated improved survival and fewer hospitalizations for worsening heart failure with extended-release (ER) metoprolol succinate in patients with heart failure. This study sought to estimate the economic implications of this trial from a US perspective. METHODS AND RESULTS: A discrete event simulation was developed to examine the course of patients with heart failure. Characteristics of the population modeled, probabilities of hospitalization and death with standard therapy, and risk reductions with ER metoprolol succinate were obtained from Metoprolol CR/XL Randomized Intervention Trial in Chronic Heart Failure (MERIT-HF) and evaluated in weekly cycles. Direct medical costs were estimated from US databases in 2001 US dollars. Uncertainty in inputs was incorporated and analyses were carried out to estimate events prevented total and net costs. The model predicts that ER metoprolol succinate will prevent approximately 7 deaths and 15 hospitalizations from heart failure per 100 patients over 2 years. Compared with standard therapy alone, this translates to a cost reduction between $395 and $1112 per patient, depending on whether the costs of hospitalizations for other causes are included. Savings were maintained in 90% of the simulations. CONCLUSION: This analysis predicts that the positive effect of ER metoprolol succinate on mortality and morbidity demonstrated in MERIT-HF leads to substantial savings.

Nyckelord

Adrenergic beta-Antagonists/administration & dosage/economics/*therapeutic
use
Adult
Aged
Aged
80 and over
Cost-Benefit Analysis
Delayed-Action Preparations
Female
Heart Failure
Congestive/*drug therapy/*economics/mortality
Hospital Costs
Hospital Mortality
Hospitalization/*economics/statistics & numerical data
Humans
Male
derivatives/economics/therapeutic use
Middle Aged
Models
Econometric
Prospective Studies
Randomized Controlled Trials
Reproducibility of Results
Survival Analysis
Treatment Outcome
United States

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy